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Abstract
Background: The increasing use of antifungal drugs (AF) in children and the concern for related adverse events
and costs has led to the development of specific AF stewardship programmes (AFS). Studies in adult patients have
shown improvements in AF prescription and usage after implementation, but paediatric data are scant. The aim of
this PROAFUNGI study was to describe the use and appropriateness of AF in a high complexity paediatric centre.
Methods: Observational, prospective, single-centre, modified point-prevalence study (11 surveys, July–October
2018), including paediatric (< 18 years) patients receiving at least one systemic AF. Prescriptions were evaluated by
the AFS team.
Results: The study included 119 prescriptions in 55 patients (53% males, median age 8.7 years [IQR 2.4–13.8]). The
main underlying condition was cancer (45.5% of patients; HSCT in 60% of them); and the first indication for AF was
prophylaxis (75 prescriptions, 63.2%). Liposomal amphotericin B was used most commonly (46% prescriptions),
mainly as prophylaxis (75%). Among the 219 evaluations, 195 (89%) were considered optimal. The reason for non-
optimal prescriptions was mostly lack of indication (14/24), especially in critical patients with ventricular assist
devices. The use of AF without paediatric approval accounted for 8/24 inappropriate prescriptions.
Conclusions: A high rate of AF appropriateness was found for the children’s hospital as a whole, in relation with a
well-established AFS. Nonetheless, the identification of specific areas of improvement should guide future actions of
the AFS team, which will focus mainly on prophylaxis in critically ill patients receiving circulatory assistance and the
use of non-approved drugs in children.
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Background
In recent years, the increase in the number of immuno-
suppressed children at risk of invasive fungal infection
(IFI) has led to a higher use of both prophylactic and
therapeutic antifungal drugs (AF) in this population [1].
In these patients, AF prescription may be challenging
due to unspecific clinical presentation, lower perform-
ance of diagnostic tests, variable pharmacokinetics re-
lated to maturation changes and lack of clinical trials in
children [1–3].
Unnecessary AF use entails substantial risk of toxicity
and interactions, along with higher drug resistances and
significant costs [3]. In the last 5 years, AF drugs
accounted for around one-third of antimicrobial usage
(13.79% of all days of therapy [DOT] per 100 patient-
days [PD]) but 75% (€638,403) of total annual anti-
infective expenditure in our hospital (unpublished data).
In response to this concern, specific AF stewardship
programmes (AFS) are being developed to improve the
clinical outcome of patients receiving AF drugs and to
ensure optimal prescription in terms of spectrum, dose,
therapeutic drug monitoring, duration and route of ad-
ministration while avoiding adverse effects and unneces-
sary costs [3]. Interventions are extrapolated from the
antibiotic stewardship programmes and include audits
with feedback, guideline and protocol development, edu-
cational programmes and prescription evaluation [4, 5].
Although AFS are relatively new, a systematic review in
2017 identified 14 papers describing AFS in adult pa-
tients and the improvements in AF prescription and use
after implementation [6]. In contrast, data about paediat-
ric AFS are scant and mainly limited to adult pro-
grammes including children or to specific situations
such as invasive Candida spp. infection or cancer [7, 8].
The aim of this PROAFUNGI study was to describe
the use and appropriateness of AF in a high complexity
paediatric centre.
Methods
The children’s hospital at Vall d’Hebron Barcelona Hos-
pital Campus is a reference tertiary care centre with a
national reference programme of solid organ transplant-
ation (SOT) and hematopoietic stem cell transplantation
(HSCT) with 35 and 40 yearly transplantations, respect-
ively, as well as a 20-bed paediatric ICU (PICU), a 44-
bed neonatal ICU (NICU) and a large surgery
programme with around 2700 inpatient procedures per
year. The institutional paediatric antimicrobial steward-
ship program (PROA-NEN) was formally founded in
2015 and aims to improve clinical outcomes, reduce
antimicrobial-related adverse events and ensure the
cost-effective use of treatments. During 2018, a specific
AFS team was created, involving 3 pharmacists, 3 paedi-
atric infectious diseases specialists and 1 microbiologist.
The PROAFUNGI study is an observational, pro-
spective, single-centre, modified point-prevalence sur-
vey (mPPS) study performed from July to October
2018. Admitted patients receiving AF were identified
through the electronic prescription system (Silicon®
v11, Grifols International, S.A., Sant Cugat del Vallès,
Spain and Centricity™ Critical Care 8.1 SP7, General
Electric Company, Barrington, United States) and data
were collected weekly. All consecutive paediatric (<
18 years) patients receiving at least one systemic AF
were included. Patients were included again if a new
AF course was started. Additionally, one AF prescrip-
tion was recorded for each week in which the drug
was prescribed. Patients receiving AF for less than 48
h were excluded.
Demographic, clinical and treatment data were
obtained from the patient’s electronic medical record
(SAP© NetWeaver 7.0 SPS37, California, United
States), including age, sex, underlying disease, AF in-
dication and IFI category. The patient’s IFI was classi-
fied as possible, probable or proven according to the
European Organization for Research and Treatment
of Cancer/Mycoses Study Group (EORTC/MSG) defi-
nitions [9]. Additionally, patients at risk of IFI and or
with clinical suspicion of IFI were added as other cat-
egories to include situations not listed in the EORTC/
MSG criteria. The AF indication was classified as
prophylaxis (primary or secondary) or treatment (em-
pirical, pre-emptive or targeted). Pharmacological data
(AF, route of administration, dose and frequency)
were collected from the abovementioned electronic
prescription systems.
After the collection, data were evaluated by two in-
dependent members of the AFS team. In case of
disagreement, a third member was consulted to
achieve consensus. Following the guidelines for the
implementation of antimicrobial stewardship programs
in Spanish hospitals, optimal prescription was defined
as “necessary” (if the clinical situation required the
use of an AF, either prophylactic and therapeutic),
“appropriate” (if the drug was active against the
causative microorganism and adjusted to the patient’s
characteristics), and “adequate” (if the dose, duration
and route of administration were correct, while in
concordance with local protocols, or international
guidelines if local protocols were not available) [10].
Qualitative variables were described as the number
and percentage, and quantitative variables as the mean ±
standard deviation (SD) or median (IQR). The statistical
analysis was carried out with Microsoft® Office Excel®
2007 (12.0.4518.1014).
The local Ethics Committee for Clinical Research
approved the study in March 2018 (code VAL-ANT-
2017-01).
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Results
Patient and fungal infection characteristics
During the study period, 55 patients were included; 53%
were males and median age was 8.7 years (IQR 2.4–13.8
years). The main underlying condition was cancer (25,
45.5%; 15 [60%] of them having undergone HSCT); and
the most common situation leading to AF prescription
was patients at risk of IFI (27; 49%). Detailed data are
provided in Table 1.
Antifungal prescription characteristics
A total of 119 AF prescriptions were analysed. The indi-
cation was prophylaxis in 75 (63.2%) cases (70 primary
and 5 secondary) and treatment in 44 (36.8%): 30 (25%)
empirical; 1 (0.8%) pre-emptive; 13 (11%) targeted. Drug
distribution by type of patient and indication is detailed
in Table 2. Most drugs (93.3%) were prescribed as
monotherapy (52 patients), while dual and triple therapy
were only used in 1 patient (2 prescriptions, 1.7%) and 2
patients (6 prescriptions, 5%), respectively.
Prescription quality assessment
During the study period, the PROAFUNGI working
group performed a total of 11 surveys, including 219
prescription evaluations. From the 219 evaluated
prescriptions, 24 (11%) were considered non-optimal. As
shown in Table 2, the main reason for a non-optimal
evaluation was lack of indication (14/24), followed by
disagreement with the local protocols (12/24), mainly in
heart-transplanted and HSCT patients. Institutional
protocols were available for 117/144 (81%) prophylactic
and 40/75 (53%) treatment prescriptions. Moreover, the
departments with the highest AF use (cancer department
and PICU) issued most non-optimal prescriptions (16.7
and 58.3%, respectively).
Liposomal amphotericin B (LAMB) was used commonly
and was also the main drug considered non-optimal
(Table 3), essentially due to non-optimal prescriptions re-
lated to prophylaxis in patients receiving circulatory assist-
ance (7/12): 2 patients with ventricular assist device (VAD)
who had an unnecessary prescription and 1 receiving extra-
corporeal membrane oxygenation (ECMO) support who had
an inappropriate prescription due to an excessive dosage.
Two non-approved drugs in paediatrics at the time of
the study, isavuconazole (5 prescriptions in one patient)
and anidulafungin (3 prescriptions in one patient),
accounted for a significant number of non-optimal pre-
scriptions due to the availability of alternative approved
drugs as empirical treatment in one patient with HSCT
and acute renal impairment who could have been
treated with oral voriconazole and one patient with por-
tal cavernomatosis who could have been treated with
micafungin, respectively.
Discussion
The present study demonstrates a significantly high
percentage of optimal prescription of AF in children at a
referral hospital but has also detected some points of im-
provement mainly related to prophylaxis in critically ill
patients receiving circulatory assistance and the use of
non-approved drugs in children.
According to previous published articles, cancer pa-
tients were those receiving AF more frequently [8, 11,
12]. In a retrospective cohort study conducted in 25
paediatric hospitals in the USA, patients with malignan-
cies represented 42% of overall AF use [11]. In our co-
hort, a large proportion of AF prescriptions were
ordered for HSCT patients (15 patients, accounting for
43 prescriptions, 36% of all AF prescriptions and 67% of
cancer patient prescriptions), as our centre is a national
referral transplant unit. Similarly, in a study including
only children with cancer, HSCT patients accounted for
78% of overall AF prescriptions [8]. Regarding patients’
age, the Antibiotic Resistance and Prescribing in Euro-
pean Children (ARPEC) study reported higher AF use in
paediatric patients (83%) compared with newborns
(17%), as did another survey including more than 50
hospitals in the USA (76 DOT/1000 patient-days in
paediatric patients compared with 14 DOT/1000
Table 1 Patient Characteristics
Total
Clinical characteristics, n 55
• Age, y, median (IQR) 8.7 (2.4–13.8)
• Male sex, n (%) 29 (53)
Underlying disease
• Cancer, n (%) 25 (45.5)
• HSCT, n (%) 15/25 (60)
• Critical paediatric patients, n (%) 14 (25.5)
• Critical newborns, n (%) 5 (9)
• Primary immunodeficiencies, n (%) 5 (9)
• Solid organ transplant, n (%) 3 (5.5)
• Other, n (%) 3 (5.5)
Clinical situationa
• Risk of IFI, n (%) 27 (49)
• Suspicion of IFI, n (%) 6 (11)
• Possible IFI, n (%) 14 (25)
• Probable IFI, n (%) 2 (4)
• Proven IFI, n (%) 6 (11)
Microorganisms
• Candida spp. 2/6
• Moulds 4/6
Abbreviations: IFI invasive fungal infection
aIFI category was defined according to the European Organization for
Research and Treatment of Cancer/Mycoses Study Group
(EORTC/MSG) definitions
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Table 2 Antifungal Prescription Characteristics and Adequacy
Total Prophylaxis Treatment
Antifungal prescriptions, n 119 75 44
Indication for AF therapy
Primary prophylaxis, n (%) 70 (58.8) 70 (93.3)
Secondary prophylaxis, n (%) 5 (4.4) 5 (6.7)
Empirical therapy, n (%) 30 (25) 30 (68.2)
Pre-emptive therapy, n (%) 1 (0.8) 1 (2.3)
Targeted therapy, n (%) 13 (11) 13 (29.5)
Underlying disease
Cancer, n (%) 64 (54) 48 (64) 16 (36.4)
HSCT, n (%) 43/64 (67) 35/48 (73) 8/16 (50)
Critical paediatric patients, n (%) 29 (24) 16 (21.4) 13 (29.5)
Critical newborns, n (%) 7 (6) 3 (4) 4 (9.1)
Primary immunodeficiencies, n (%) 11 (9) 7 (9.3) 4 (9.1)
Solid organ transplant, n (%) 3 (3) 0 (0) 3 (6.8)
Other, n (%) 5 (4) 1 (1.3) 4 (9.1)
AF agent
Liposomal amphotericin B, n (%) 55 (46.2) 41 (54.6) 14 (32)
Posaconazole, n (%) 21 (17.7) 21 (28) 0 (0)
Anidulafungin, n (%) 13 (10.9) 3 (4) 10 (23)
Fluconazole, n (%) 12 (10.1) 6 (8) 6 (14)
Micafungin, n (%) 6 (5.0) 2 (2.7) 4 (9)
Isavuconazole, n (%) 5 (4.2) 0 (0) 5 (11)
Voriconazole, n (%) 4 (3.4) 0 (0) 4 (9)
Itraconazole, n (%) 2 (1.7) 2 (2.7) 0 (0)
Caspofungin, n (%) 1 (0.8) 0 (0) 1 (2)
Antifungal prescription evaluations, n 219 144 75
Non-optimal prescriptions, n (%) 24 (11) 12 (8) 12 (16)
Unnecessary, n (%) 14 (6) 10 (7) 4 (5)
Inappropriate, n (%) 2 (1) 0 (0) 2 (3)
Inadequate Incorrect dose, n (%) 7 (3) 4 (3) 3 (4)
Incorrect route of administration, n (%) 0 (0) 0 (0) 0 (0)
Incorrect duration, n (%) 7 (3) 7 (5) 0 (0)
Disagreement with institutional protocol, when available, n (%) 12 (8)a 4 (3)a 8 (20)a
Non-optimal prescription distribution among underlying disease, n (%)
Cancer 4 (16.7) 2 (16.7) 2 (16.7)
HSCT, n (%) 4/4 (100) 2/2 (100) 2/2 (100)
Critical paediatric patients, n (%) 14 (58.3) 8 (66.7) 6 (50)
Critical newborns, n (%) 1 (4.2) 1 (8.3) 0 (0)
Primary immunodeficiencies, n (%) 1 (4.2) 1 (8.3) 0 (0)
Solid organ transplant, n (%) 1 (4.2) 0 (0) 1 (8.3)
Other, n (%) 3 (12.5) 0 (0) 3 (25)
Abbreviations: AF antifungal
a Calculated as a percentage of the prescriptions for which a local institutional protocol was available: 157 total, 117 prophylaxis, 40 treatment
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patient-days in newborns) [12, 13]. Remarkably, AF use
in neonates was even lower in our centre (5 patients, ac-
counting for 7 prescriptions, 6%), in relation to a mini-
mum incidence of neonatal candidiasis (0.6%) that
precludes the use of universal AF prophylaxis in low
birth weight neonates [14, 15].
Regarding AF indication, prophylaxis was the main
reason for prescriptions (63.2%), followed by empirical
treatment (25%) and targeted treatment (11%). These
findings are consistent with data from the study per-
formed by Santiago-García et al. that included 56 chil-
dren with cancer and also the arm of paediatric patients
from the ARPEC study [8, 12]. In the neonate arm,
prophylaxis was the reason for 46% of prescriptions,
while treatment of suspected candidaemia accounted for
the other 44% [12].
In terms of the distribution of AF, LAMB was the
most prescribed drug in our study, followed by posaco-
nazole. At our hospital, low-dose LAMB is the drug of
choice for AF prophylaxis in high-risk cancer patients
(relapsed or refractory leukaemia, HSCT pre-
engraftment phase) due to its effectiveness and safety
profile as shown in a previous paper by our group [16].
LAMB is also used in critically ill paediatric patients due
to its stability with the concomitant use of continuous
renal replacement therapy, as opposed to azole elimin-
ation [17]. On the other hand, posaconazole is mainly
indicated in the HSCT post-engraftment period and in
some primary immunodeficiencies (PID) such as chronic
granulomatous disease. These data was quite different
from other studies in which fluconazole is the most
commonly prescribed agent [7, 11–13]. Nonetheless, all
these studies include a high proportion, or exclusively
include, neonates in whom Candida spp. is the main
and almost only fungal pathogen [7, 11, 12]. Conversely,
for paediatric, particularly children with cancer, PID or
HSCT (a majority in our cohort), filamentous fungi
should be considered, and other AFs with a broader
spectrum play a major role [2, 10, 18, 19].
Regarding AF prescription evaluations, a high pro-
portion (89%) of prescriptions were considered cor-
rect, similar to the study by Santiago-García et al.,
that described 93% of appropriate AF prescriptions in
a paediatric cancer department [8]. In contrast, a
multicentric study by Ferreras-Antolín et al. consid-
ered that only 34% of prescriptions were optimal,
similar to another study focused on adult patients
with hospital-acquired candidemia that found 47% of
correct prescriptions [7, 20]. Remarkably, the level of
non-optimal prescriptions was higher in patients re-
ceiving treatment (12/75; 16%) compared with
prophylaxis (12/144, 8%), probably due to the higher
availability of institutional protocols aimed at prophy-
laxis. Protocols were available for 117/144 (81%)
prophylactic prescriptions and for 40/75 (53%) treat-
ment prescriptions.
Regarding the cause of incorrect prescription, the lead-
ing reason was the lack of indication (unnecessary) (14/
24), followed by disagreement with current recommen-
dations (12/24), incorrect dose (7/24), incorrect duration
(7/24) and inappropriate choice of AF (2/24). Interest-
ingly, the proportions were generally similar to Santiago-










27 105 12 (11%) - Unnecessary (9)
- Inappropriate (2)
- Inadequate: incorrect dose (5), incorrect duration (7),
disagreement with institutional protocol b (5)
Posaconazole 12 32 1 (3%) - Inadequate, incorrect dose (1)
Anidulafungin 11 29 3 (10%) - Unnecessary (3)
Fluconazole 11 25 1 (4%) - Inadequate, incorrect dose (1)
Isavuconazole 2 9 5 (56%) - Inadequate: disagreement with institutional
protocol** (5)
Micafungin 3 7 2 (29%) - Unnecessary (2)
- Inadequate: disagreement with institutional
protocol b (2)
Voriconazole 2 5 0 N/A
Caspofungin 1 4 0 N/A
Itraconazole 2 3 0 N/A
Abbreviations: N/A not applicable
a The same prescription may not be optimal for more than one reason
b Disagreement with institutional protocol, when available
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Garcia et al., that described the lack of indication as the
main cause of non-optimal prescription (7/13), followed
by incorrect dosage (5/13) or incorrect route of adminis-
tration (1/13) [8].
Some incorrect prescriptions were related to drugs not
approved for paediatric use at the time of study (such as
anidulafungin or isavuconazole). Although these drugs
have shown clinical benefits in adults, paediatric use
should be carefully evaluated and restricted to cases with
no approved alternative for children. Moreover, for im-
proving prescription’s quality, decisions regarding anti-
fungals should be made by a multi-disciplinary team. In
centres with persuasive ASP, following experts’ advice is
of utmost importance.
With regards to dose, the incorrect rate (3%) was sig-
nificantly lower than in a previous study by Lestner et al.
that found an inadequate dose as the main cause of in-
correct AF use in paediatrics, identifying 47% of cases
with doses lower than recommended by international
guidelines [12]. The existence of specific tools for
electronic prescription and the daily revision by the
Pharmacy Department have probably contributed to this
high rate of adequate dosing.
The limitations of this study were its single-centre na-
ture and its PPS format, which may have meant that
some prescriptions were missed. Moreover, a 4-month
period including 11 surveys may not be sufficiently rep-
resentative of overall practice, as several periods of viral
epidemics can produce fever without bacterial cause and
thus lead to increased empirical AF use. However, the
results of this study regarding AF use are similar to an-
nual AF consumption (DOT/100 PD) in our hospital
(unpublished data). In 2018, most AF usage occurred in
standard hospitalization patients, followed by PICU pa-
tients (63 and 34%, respectively). In our cohort, these pa-
tients accounted for 70 and 24% of prescriptions,
respectively. By therapeutic group, the AFs used most
often in 2018 were azoles (45% DOT/100 PD), LAMB
(32% DOT/100 PD), and echinocandins (23% DOT/100
PD). In terms of AF distribution in this PROAFUNGI
study; LAMB was the most prescribed drug (46.2%),
followed by azoles (37%) and echinocandins (16.7%).
Conclusions
A high rate of optimal AF evaluation was globally dem-
onstrated for all areas of a tertiary children’s hospital, in
relation to a well-established ASP that performs weekly
audits and agreed protocols. However, this study identi-
fied specific areas of improvement, most of them related
to the lack of an institutional protocol. These findings
will guide the next actions of the AFS team, which will
focus mainly on critical patients and the use of non-
approved drugs in children.
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